Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | MIST |
---|---|---|
09:32 ET | 425 | 1.43 |
09:43 ET | 1944 | 1.42 |
09:50 ET | 13160 | 1.3836 |
09:54 ET | 700 | 1.41 |
09:59 ET | 500 | 1.4099 |
10:03 ET | 445 | 1.4011 |
10:06 ET | 10100 | 1.36 |
10:10 ET | 500 | 1.38 |
10:12 ET | 6024 | 1.365 |
10:14 ET | 3800 | 1.375 |
10:19 ET | 2200 | 1.37 |
10:21 ET | 4000 | 1.38 |
10:24 ET | 2000 | 1.3799 |
10:30 ET | 200 | 1.3795 |
10:32 ET | 200 | 1.375 |
10:33 ET | 185 | 1.38 |
10:39 ET | 300 | 1.3799 |
10:46 ET | 400 | 1.39 |
10:48 ET | 4300 | 1.41 |
10:50 ET | 2900 | 1.42 |
11:04 ET | 4365 | 1.42 |
11:15 ET | 100 | 1.4366 |
11:22 ET | 200 | 1.4201 |
11:24 ET | 1100 | 1.41 |
11:38 ET | 1200 | 1.41 |
11:44 ET | 100 | 1.41 |
12:05 ET | 100 | 1.41 |
12:27 ET | 1000 | 1.415 |
12:39 ET | 1900 | 1.41 |
12:59 ET | 100 | 1.4 |
01:06 ET | 100 | 1.41 |
01:21 ET | 100 | 1.405 |
01:28 ET | 100 | 1.405 |
01:53 ET | 300 | 1.4091 |
02:06 ET | 100 | 1.41 |
02:40 ET | 100 | 1.41 |
02:44 ET | 100 | 1.405 |
03:07 ET | 510 | 1.4 |
03:16 ET | 500 | 1.3999 |
03:20 ET | 111 | 1.3987 |
03:27 ET | 300 | 1.4 |
03:36 ET | 100 | 1.4 |
03:45 ET | 100 | 1.395 |
03:48 ET | 7737 | 1.405 |
03:52 ET | 486 | 1.4 |
03:54 ET | 200 | 1.4 |
03:56 ET | 682 | 1.4 |
03:57 ET | 222 | 1.4014 |
03:59 ET | 255 | 1.41 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Milestone Pharmaceuticals Inc | 75.6M | -1.1x | --- |
Barinthus Biotherapeutics PLC | 74.2M | -1.0x | --- |
Bioatla Inc | 76.0M | -0.6x | --- |
Checkpoint Therapeutics Inc | 74.4M | -0.9x | --- |
Entera Bio Ltd | 78.4M | -7.2x | --- |
MediciNova Inc | 66.2M | -7.8x | --- |
Milestone Pharmaceuticals Inc. is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The Company is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia (PSVT) with a subsequent indication to treat atrial fibrillation with rapid ventricular rate (AFib-RVR) and other cardiovascular indications.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $76.2M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 53.3M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.65 |
EPS | $-1.25 |
Book Value | $0.50 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.